GSK2126458

Product description: GSK2126458 is an orally available selective inhibitor of the class I phosphoinositide 3-kinase (PI3K) enzymesand MTOR1/2 complexes. GSK2126458 can inhibit PI3K-alpha (p85alpha/p110alpha) with IC(50) of 0.04nM. GSK2126458 has Ki values in the picomolar range for each of the class I PI3K isoforms and MTOR1/2 complexes. GSK2126458 has potent in vitro and in vivo growth-inhibitory effects on cancer cells. In comparison with other clinical PI3K inhibitors, GSK2126458 is around 100-fold more potent than BEZ235 (6nM). GSK2126458 also a low picomolar inhibitor of the common activating mutants of p110R ( E542K, E545K, and H1047R ) with Ki of 0.008nM, 0.008nM and 0.009nM in human cancer. In mechanistic cellular assays, GSK2126458 caused a significant reduction in the levels of pAKT-S473 with remarkable potency. Consistent with its activity against both PI3K R and mTOR, GSK2126458 also inhibits phosphorylation of AKT-T308 and p70S6K at low nanomolar concentrations. GSK2126458 induces a G1 cell cycle arrest and inhibits cell proliferation in a large panel of cell lines, including T47D and BT474 breast cancer lines.

Alternate Names/Synonyms: HYR-582

Product Type: Chemical

Molecular Formula: C25H17F2N5O3S

Molecular Weight: 505.5

CAS: 1086062-66-9

Purity: >95%

InChiKey: CGBJSGAELGCMKE-UHFFFAOYSA-N

Appearance Solid.

Solubility: Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol.

Short Term Storage: +4°C

Long Term Storage: -20°C

Shipping: AMBIENT

Use & Stability: Stable for at least 2 years after receipt when stored at -20°C.

Lien vers la Fiche Technique